People · Operator
Named in public records as an officer, director or promoter · active 2014–2024 · Other, Biotech / Pharma
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Immusoft Corp | — | Other | Series A | $24.0M | $21.5M | 2014 |
| Oisin Biotechnologies, Inc. | — | Biotech / Pharma | Series A | $18.4M | $28.1M | 2020 |
| OncoSenX, Inc. | — | Other | Series A | $4.8M | $7.2M | 2021 |
Eric Garcia at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Eric Garcia on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Matthew Scholz | 3 | 3 |
| John Lewis | 2 | 6 |
| Gary Hudson | 2 | 3 |
| Stephen Hilbert | 2 | 2 |
| Anthony Sun | 1 | 8 |
| Sean Ainsworth | 1 | 5 |
| Julia Moore | 1 | 3 |
| Rich Vincent | 1 | 3 |
| Julia C/o Moore | 1 | 1 |
| Wendell C/o King | 1 | 1 |
| Sean C/o Ainsworth | 1 | 1 |
| Matthew C/o Scholz | 1 | 1 |
| Wendell King | 1 | 1 |
| Scott McIvor | 1 | 1 |
| Eric Herbig | 1 | 1 |
| Richard Chin, M.D. | 1 | 1 |
| Mark Ahn, Ph.D. | 1 | 1 |
| David Gobel | 1 | 1 |
| Danjuma Quarless | 1 | 1 |
| Steve Hilbert | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.